SORT BY

FILTER BY

also on other fortune lists

company facts

g500 stats

Global 500

Martin Leissl — Bloomberg via Getty Images

255

Merck

MRK

U.S.

Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant’s wide-ranging portfolio was crucial to that haul–but the company’s next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb’s competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.

Looking for leads, investment insights, or competitive intelligence?

CEO

Kenneth C. Frazier

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Kenilworth, NJ

Years on Global 500 List

23

Employees

68,000

Key Financials (Last Fiscal Year)
($ Millions)% change
Revenues ($M)$39,8070.8%
Profits ($M)$3,920.0-11.8%
Assets ($M)$95,377
Total Stockholder Equity ($M)$40,088
Profit Ratios
Profit as % of Revenues9.8%
Profits as % of Assets4.1%
Profits as % of Stockholder Equity9.8%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Merck

Fortune's World's Great Leaders List

This year's list is all about new power. Number one? The kids of Marjory Stoneman Douglas High School.

Read More →
Merck's Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half.

Read More →